The SK-N-SH cell line was isolated in 1970 from the brain tissue extracted from a 4-year-old female patient suffering from a neuroblastoma. These cells are ideal as transfection hosts because they are known to express high levels of dopamine-beta-hydroxylase and having a higher doubling time. SK-N-SH are used in biomedical research for certain types of brain cancer. Altogen Biosystems manufactures and prepares a SK-N-SH transfection reagent that is cationic lipid based with a high transfection efficacy. This reagent is proven to establish stable cell lines for reliable yields.
Derived from the metastasized neuroblastoma of a young human female, the SK-N-SH cell line is one of the primary in vitro models for brain cancer drug development and testing of novel immunotherapies. With neurite outgrowths and modulated differentiation, SK-N-SH complement dopamine-beta-hydroxylase expression with a physiology that closely follows that of live neuroblastoma tissue in vivo . With cancer-specific transfection reagents , research involving the screening of siRNA sequences can show how RNA interference technology could be used to combat cancer proliferation even after metastasis.